Diquafosol

Diquafosol
Names
	IUPAC name [[[[(2R,3S,4R,5R)-5-(2,4-Dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate
	Other names P1,P4-Bis(5'-uridyl) tetraphosphate; INS-365; Diquafosol tetrasodium
Identifiers
CAS Number	59985-21-6 ; 211427-08-6 (tetrasodium salt) ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL1767408; ChEMBL221326;
ChemSpider	130647; 130646 (tetrasodium salt);
IUPHAR/BPS	1736;
PubChem CID	148197; 148196 (tetrasodium salt);
UNII	7828VC80FJ;
CompTox Dashboard (EPA)	DTXSID40208689 ;
	InChI InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1 Key: NMLMACJWHPHKGR-NCOIDOBVSA-N; InChI=1/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1 Key: NMLMACJWHPHKGR-NCOIDOBVBD;
	SMILES O=C1\C=C/N(C(=O)N1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]4O[C@@H](N\3C(=O)NC(=O)/C=C/3)[C@H](O)[C@@H]4O;
Properties
Chemical formula	C18H26N4O23P4
Molar mass	790.306 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010.[1] It is formulated as a 3% ophthalmic solution of the tetrasodium salt.

Its mechanism of action involves agonism of the P2Y2 purinogenic receptor.[2]

References

"Santen and Inspire Announce Approval of DIQUAS for Dry Eye Treatment in Japan". April 16, 2010.
Pendergast, W; Yerxa, BR; Douglass Jg, 3rd; Shaver, SR; Dougherty, RW; Redick, CC; Sims, IF; Rideout, JL (2001). "Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates". Bioorganic & Medicinal Chemistry Letters. 11 (2): 157–60. doi:10.1016/S0960-894X(00)00612-0. PMID 11206448.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Santen and Inspire Announce Approval of DIQUAS for Dry Eye Treatment in Japan". April 16, 2010.

[2] Pendergast, W; Yerxa, BR; Douglass Jg, 3rd; Shaver, SR; Dougherty, RW; Redick, CC; Sims, IF; Rideout, JL (2001). "Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates". Bioorganic & Medicinal Chemistry Letters. 11 (2): 157–60. doi:10.1016/S0960-894X(00)00612-0. PMID 11206448.